American International Group, Inc. Viridian Therapeutics, Inc.\De Transaction History

American International Group, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$17.09 - $23.82 $55,815 - $77,796	3,266 Added 15.37%	24,515 $429,000
Q4 2023 Feb 13, 2024	BUY	$11.12 - $22.5 $2,101 - $4,252	189 Added 0.9%	21,249 $462,000
Q3 2023 Nov 13, 2023	BUY	$15.16 - $24.7 $11,339 - $18,475	748 Added 3.68%	21,060 $323,000
Q2 2023 Aug 04, 2023	BUY	$22.57 - $29.67 $42,002 - $55,215	1,861 Added 10.09%	20,312 $483,000
Q1 2023 May 12, 2023	BUY	$25.04 - $37.6 $14,047 - $21,093	561 Added 3.14%	18,451 $469,000
Q4 2022 Feb 10, 2023	BUY	$18.78 - $29.74 $99,458 - $157,503	5,296 Added 42.05%	17,890 $522,000
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $5,521 - $13,158	516 Added 4.27%	12,594 $258,000
Q2 2022 Aug 12, 2022	BUY	$9.55 - $19.0 $115,344 - $229,482	12,078 New	12,078 $140,000

179

76.8M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $839M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.